Stock 2160 GNI GROUP LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company GNI Group Ltd.

Equities

2160

JP3386370005

Biotechnology & Medical Research

Delayed Japan Exchange
Other stock markets
 01:24:35 2024-04-30 am EDT 		5-day change 1st Jan Change
2,504 JPY -0.24% Intraday chart for GNI Group Ltd. +0.93% -11.41%
Mar. 19 Jefferies Adjusts GNI Group’s Price Target to 4,100 Yen From 3,000 Yen, Keeps at Buy MT
Feb. 14 GNI Group Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 2024 CI

Business Summary

GNI Group Ltd is a Japan-based company engaged in pharmaceutical business and medical device business. The Company conducts global pharmaceutical research and development, manufacturing and distribution and biomaterials business. The Company operates in two business segments. The Pharmaceuticals segment conducts research and development, manufacturing, and sale of developed compounds, including ETUARY sold in the China market and Hydronidone (F351), which is in clinical trials. The main products also include other pharmaceuticals and reagents. The Medical Devices segment develops, manufactures, and sells medical devices such as biomaterials in the United States. This segment also includes medical device Designated Marketing Authorization Holder (DMAH) and In-Country Caretaker (ICC) services. The Company also conducts clinical and business development in the United States and conducts clinical development of F351 for Metabolic Dysfunction-Associated Steatohepatitis in the United States.

Number of employees: 843

Sales per Business

JPY in Million2022Weight2023Weight Delta
Pharmaceutical
88.3 %
14,991 86.1 % 22,976 88.3 % +53.26%
Medical Devices
11.7 %
2,428 13.9 % 3,034 11.7 % +24.99%

Sales per region

JPY in Million2022Weight2023Weight Delta
China
65.8 %
14,871 85.4 % 17,123 65.8 % +15.15%
Japan
23.1 %
21 0.1 % 6,021 23.1 % +28,631.54%
United States
11.0 %
2,527 14.5 % 2,866 11.0 % +13.41%

Managers

Managers TitleAgeSince
Ying Luo FOU
 Founder 58 05-05-31
Toshiya Kitagawa DFI
 Director of Finance/CFO - 23-07-02
Kanichiro Suzuki BRD
 Director/Board Member - -
Thomas Eastling BRD
 Director/Board Member 64 13-02-28

Members of the board

Members of the board TitleAgeSince
Hao Yan BRD
 Director/Board Member 61 -
Hideaki Sashiwa BRD
 Director/Board Member 65 08-05-31
Ying Luo FOU
 Founder 58 05-05-31
Kazuki Sekitani BRD
 Director/Board Member 67 23-03-29
Thomas Eastling BRD
 Director/Board Member 64 13-02-28
Kanichiro Suzuki BRD
 Director/Board Member - -
Kanako Kikuchi BRD
 Director/Board Member 61 23-03-29
Ryosuke Matsui BRD
 Director/Board Member 45 23-03-29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 49,893,243 48,202,820 ( 96.61 %) 13,526 ( 0.0271 %) 96.61 %

Shareholders

NameEquities%Valuation
Heights Capital Management, Inc.
4.398 %
2,193,200 4.398 % 45 M ¥
Ying Luo
2.903 %
1,447,712 2.903 % 30 M ¥
Sydbank A/S (Investment Management)
0.2328 %
116,100 0.2328 % 2 M ¥
Kanichiro Suzuki
0.0988 %
49,300 0.0988 % 1 M ¥
SEI Investments (Europe) Ltd.
0.0561 %
28,000 0.0561 % 575 374 ¥
Dimensional Fund Advisors Ltd.
0.0430 %
21,457 0.0430 % 440 922 ¥
FIL Investments (Japan) Ltd.
0.0335 %
16,695 0.0335 % 343 067 ¥
Mercer Global Investments Europe Ltd.
0.0162 %
8,100 0.0162 % 166 448 ¥
KLP Kapitalforvaltning AS
0.0148 %
7,400 0.0148 % 152 063 ¥
DFA Australia Ltd.
0.005815 %
2,900 0.005815 % 59 592 ¥

Holdings

NameEquities%Valuation
Gyre Therapeutics, Inc.
83.58%
 64,005,887 83.58% 1,118,822,905 $
GNI GROUP LTD.
0.00%
 1,400 0.00% 28,769 $

Company contact information

GNI Group Ltd.

Nihonbashi-Honcho YS Building, 3/F 2-2-2 Nihonbashi-Honcho

103-0023, Tokyo

+81 3 6214 3600

http://www.gnipharma.com
address GNI Group Ltd.(2160)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for GNI Group Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2,510 JPY
Average target price
4,100 JPY
Spread / Average Target
+63.35%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GNI GROUP LTD. Stock GNI Group Ltd.
-11.31% 795M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.77% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+12.24% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.44% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.01% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.56% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.82% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 2160 Stock
  4. Company GNI Group Ltd.